Artificial intelligence and machine learning technologies have significant potential, but regulatory hurdles may stand in their way.
The revolution in data and technology should be pushing companies to focus on safeguarding intellectual property.
Topics from regenerative medicine to artificial intelligence to cannabis will be discussed.
After a series of delays and false starts, EMA is now progressing its ISO IDMP agenda with firm intent. The first implementation guide is out now for consultation, to be followed by a second actionable version by next year. Life sciences companies targeting Europe will have a year to comply with all the measures—but this will be a lot of work.
A recent report from Frost & Sullivan anticipates strong market growth but also points to opportunity for more vulnerabilities.
A recent paper released by Duke University cites the promise of AI, but urges policy changes in order to bring AI-enabled clinical decision software to fruition.
Successful integration requires a rethinking around the role of data science in product design and lifecycle management.
It is time to extend AI’s use into labor & delivery departments, where the technology can help guide care teams to mitigate risks and make informed decisions.
Smart technologies will continue to play a big role in advancing decision-making efforts.
The race to apply AI to medical treatment is rapidly accelerating in China and Japan.